Primary biliary cirrhosis surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 10: | Line 10: | ||
*Decompensated [[cirrhosis]] | *Decompensated [[cirrhosis]] | ||
*Endstage [[liver failure]] | *Endstage [[liver failure]] | ||
*Indications specific to endstage [[liver failure]]: | *Indications specific to endstage [[liver failure]] include: | ||
**Refractory [[ascites]] | **Refractory [[ascites]] | ||
**Recurrent [[spontaneous bacterial peritonitis]] | **Recurrent [[spontaneous bacterial peritonitis]] | ||
| Line 17: | Line 17: | ||
**[[Hepatorenal syndrome|Hepatorenal syndrome type I]] | **[[Hepatorenal syndrome|Hepatorenal syndrome type I]] | ||
**[[Hepatocellular carcinoma]] | **[[Hepatocellular carcinoma]] | ||
*Indications specific to | *Indications specific to primary biliary cirrhosis include: | ||
**Refractory [[pruritus]] | **Refractory [[pruritus]] | ||
**Chronic [[fatigue]] | **Chronic [[fatigue]] | ||
| Line 35: | Line 35: | ||
== Recurrence == | == Recurrence == | ||
* | *The recurrence of [[Primary biliary cirrhosis|primarybiliary cirrhosis]] following [[Liver transplantation|liver transplantation]]:<ref name="pmid14594139">{{cite journal |vauthors=MacQuillan GC, Neuberger J |title=Liver transplantation for primary biliary cirrhosis |journal=Clin Liver Dis |volume=7 |issue=4 |pages=941–56, ix |year=2003 |pmid=14594139 |doi= |url=}}</ref><ref name="pmid21459072">{{cite journal |vauthors=Carbone M, Neuberger J |title=Liver transplantation in PBC and PSC: indications and disease recurrence |journal=Clin Res Hepatol Gastroenterol |volume=35 |issue=6-7 |pages=446–54 |year=2011 |pmid=21459072 |doi=10.1016/j.clinre.2011.02.007 |url=}}</ref><ref name="pmid11084062">{{cite journal |vauthors=Gilroy RK, Lynch SV, Strong RW, Kerlin P, Balderson GA, Stuart KA, Crawford DH |title=Confirmation of the role of the Mayo Risk Score as a predictor of resource utilization after orthotopic liver transplantation for primary biliary cirrhosis |journal=Liver Transpl. |volume=6 |issue=6 |pages=749–52 |year=2000 |pmid=11084062 |doi=10.1053/jlts.2000.9746 |url=}}</ref><ref name="pmid11084062">{{cite journal |vauthors=Gilroy RK, Lynch SV, Strong RW, Kerlin P, Balderson GA, Stuart KA, Crawford DH |title=Confirmation of the role of the Mayo Risk Score as a predictor of resource utilization after orthotopic liver transplantation for primary biliary cirrhosis |journal=Liver Transpl. |volume=6 |issue=6 |pages=749–52 |year=2000 |pmid=11084062 |doi=10.1053/jlts.2000.9746 |url=}}</ref><ref name="pmid8750166">{{cite journal |vauthors=Dubel L, Farges O, Bismuth H, Sebagh M, Homberg JC, Johanet C |title=Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis |journal=J. Hepatol. |volume=23 |issue=6 |pages=674–80 |year=1995 |pmid=8750166 |doi= |url=}}</ref><ref name="pmid20526013">{{cite journal |vauthors=Ciesek S, Becker T, Manns MP, Strassburg CP |title=Anti-parietal cell autoantibodies (PCA) in primary biliary cirrhosis: a putative marker for recurrence after orthotopic liver transplantation? |journal=Ann Hepatol |volume=9 |issue=2 |pages=181–5 |year=2010 |pmid=20526013 |doi= |url=}}</ref> | ||
**About 20% at 5 years | |||
**About 30% at 10 years | |||
**About 40% at 15 years | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 16:16, 6 February 2018
|
Primary Biliary Cirrhosis Microchapters |
|
Differentiating Primary Biliary Cirrhosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary biliary cirrhosis surgery On the Web |
|
American Roentgen Ray Society Images of Primary biliary cirrhosis surgery |
|
Risk calculators and risk factors for Primary biliary cirrhosis surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2]
Overview
The mainstay of treatment for primary primarybiliary cirrhosis is medical therapy. Surgery is usually reserved for patients with either decompensated cirrhosis and endstage liver failure who do not show any improvement with medical therapy.
Indications
Indications for liver transplantation include:
- Decompensated cirrhosis
- Endstage liver failure
- Indications specific to endstage liver failure include:
- Refractory ascites
- Recurrent spontaneous bacterial peritonitis
- Recurrent variceal hemorrhage
- Hepatic encephalopathy
- Hepatorenal syndrome type I
- Hepatocellular carcinoma
- Indications specific to primary biliary cirrhosis include:
Surgery
- The mainstay of treatment for primarybiliary cirrhosis is medical therapy. Liver transplantation is usually reserved for patients with either:
- Decompensated cirrhosis
- Endstage liver failure
- Liver transplantation is considered to be the only definitive treatment for PBC with decompensated cirrhosis and endstage liver failure.
- The 5 year survival rate following liver transplantation is up to 85%, which is the highest in any liver disease.
- "Model for end-stage liver disease” (MELD) score is used to govern priority for liver transplantation.[1]
- The score range between 6 and 40 and is calculated using a logarithmic assessment of three objective and reproducible variables including:
- Total serum bilirubin
- Creatinine concentrations
- International normalized ratio
- As per European Association for the Study of the Liver(EASL) guidelines the MELD score of over 12 should be evaluated for potential liver transplantation in PBC.
Recurrence
- The recurrence of primarybiliary cirrhosis following liver transplantation:[2][3][4][4][5][6]
- About 20% at 5 years
- About 30% at 10 years
- About 40% at 15 years
References
- ↑ Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P; et al. (2003). "Model for end-stage liver disease (MELD) and allocation of donor livers". Gastroenterology. 124 (1): 91–6. doi:10.1053/gast.2003.50016. PMID 12512033.
- ↑ MacQuillan GC, Neuberger J (2003). "Liver transplantation for primary biliary cirrhosis". Clin Liver Dis. 7 (4): 941–56, ix. PMID 14594139.
- ↑ Carbone M, Neuberger J (2011). "Liver transplantation in PBC and PSC: indications and disease recurrence". Clin Res Hepatol Gastroenterol. 35 (6–7): 446–54. doi:10.1016/j.clinre.2011.02.007. PMID 21459072.
- ↑ 4.0 4.1 Gilroy RK, Lynch SV, Strong RW, Kerlin P, Balderson GA, Stuart KA, Crawford DH (2000). "Confirmation of the role of the Mayo Risk Score as a predictor of resource utilization after orthotopic liver transplantation for primary biliary cirrhosis". Liver Transpl. 6 (6): 749–52. doi:10.1053/jlts.2000.9746. PMID 11084062.
- ↑ Dubel L, Farges O, Bismuth H, Sebagh M, Homberg JC, Johanet C (1995). "Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis". J. Hepatol. 23 (6): 674–80. PMID 8750166.
- ↑ Ciesek S, Becker T, Manns MP, Strassburg CP (2010). "Anti-parietal cell autoantibodies (PCA) in primary biliary cirrhosis: a putative marker for recurrence after orthotopic liver transplantation?". Ann Hepatol. 9 (2): 181–5. PMID 20526013.